Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf Stadler

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 17, 2024
Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour groupKhaled Elsayad, Emmanuella Guenova, Chalid Assaf, et al.
The British Journal of Dermatology|May 27, 2025
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part two: treatmentEmmilia Hodak, Iris Amitay-Laish, Martine Bagot, et al.
The British Journal of Dermatology|May 27, 2025
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and stagingEmmilia Hodak, Iris Amitay-Laish, Martine Bagot, et al.
The Lancet. Haematology|February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialRudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
The British Journal of Dermatology|April 10, 2024
Paediatric-onset lymphomatoid papulosis: results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)Maël Blanchard, Marie-Anne Morren, Anne-Marie Busschots, et al.
Blood|November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A Olsen, Sean Whittaker, Rein Willemze, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Fungi (Basel, Switzerland)|October 8, 2020
Spread of Terbinafine-Resistant <i>Trichophyton mentagrophytes</i> Type VIII (India) in Germany-"The Tip of the Iceberg?"Pietro Nenoff, Shyam B Verma, Andreas Ebert, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|October 17, 2024
Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour groupKhaled Elsayad, Emmanuella Guenova, Chalid Assaf, et al.
The British Journal of Dermatology|May 27, 2025
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part two: treatmentEmmilia Hodak, Iris Amitay-Laish, Martine Bagot, et al.
The British Journal of Dermatology|May 27, 2025
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and stagingEmmilia Hodak, Iris Amitay-Laish, Martine Bagot, et al.
The Lancet. Haematology|February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialRudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
The British Journal of Dermatology|April 10, 2024
Paediatric-onset lymphomatoid papulosis: results of a multicentre retrospective cohort study on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)Maël Blanchard, Marie-Anne Morren, Anne-Marie Busschots, et al.
Blood|November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A Olsen, Sean Whittaker, Rein Willemze, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Fungi (Basel, Switzerland)|October 8, 2020
Spread of Terbinafine-Resistant <i>Trichophyton mentagrophytes</i> Type VIII (India) in Germany-"The Tip of the Iceberg?"Pietro Nenoff, Shyam B Verma, Andreas Ebert, et al.
Pageof 15